Observational study of AML with NPM1 mutation
Part of Blood & lymphatic, Cancer clinical trials.
This study is observing leukemia patients who have a certain gene change (NPM1 mutation) to better understand their disease and early blood vessel problems.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- You must have been diagnosed with a new, untreated acute myeloid leukemia (AML) since January 2015.
- Your leukemia must have a specific change in a gene called NPM1.
- Your doctor must have done a special test at diagnosis to look at the proteins on your leukemia cells (immunophenotyping).
- You must be willing to sign a consent form allowing your medical data to be used in this study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug combination called VA against a standard chemotherapy (3+7) for older adults newly diagnosed with a type of AML that has changes in the NPM1 or IDH1/IDH2 genes. It aims to see which treatment works better and is safer.
This trial looks at how childhood, teen, and young adult acute myeloid leukemia (AML) changes at the genetic level and how cells respond to multiple drugs. It may help doctors understand which treatments work best and how leukemia interacts with supportive cells in the bone marrow.
This early-phase study tests a menin inhibitor drug (SNDX-5613) combined with standard induction chemotherapy (daunorubicin plus cytarabine) in newly diagnosed AML with specific gene changes (NPM1 or FLT3 status, or MLL/KMT2A or NUP98). It may help patients whose AML has these genetic features respond better to intensive treatment.
This study looks at how a new drug called a menin inhibitor works in patients with acute myeloid leukemia (a blood cancer) who have relapsed after receiving a stem cell transplant. Researchers want to understand which patients benefit most by studying specific markers in their blood.
This trial tests a new drug called HMPL-306 in people with acute myeloid leukemia (AML) that has not responded to treatment or has come back. It is for patients whose leukemia cells have a specific change in the IDH1 or IDH2 gene.
This trial tests a combination of two drugs (an IDO1 inhibitor and a PD-1 blocker) given with standard chemotherapy (azacitidine and venetoclax) for people newly diagnosed with acute myeloid leukemia (AML) who cannot have intensive chemotherapy. The goal is to see if this approach helps the immune system fight the leukemia better.
Hear when a new Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.